Dalton, William S.

Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells

Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity

Cytokine Signaling Pathways and InteractionsMultiple Myeloma Research and Treatments

Cited by 1,638

Environment-mediated drug resistance: A major contributor to minimal residual disease

Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer

Cancer Cells and MetastasisAcute Lymphoblastic Leukemia research

Cited by 892

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 523

Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death

Hazlehurst, L. A., Landowski, T. H., & Dalton, W. S. (2003) · Oncogene

Cancer Cells and MetastasisCell death mechanisms and regulation

Cited by 203

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 162

Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects

Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology

Cytokine Signaling Pathways and InteractionsImmune cells in cancer

Cited by 131

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

Mostofa, A., Distler, A., Meads, M. B., Sahakian, E., Powers, J. J., Achille, A., Noyes, D., Wright, G., Fang, B., Izumi, V., et al. (2021) · JCI Insight

Multiple Myeloma Research and TreatmentsHistone Deacetylase Inhibitors Research

Cited by 27